Moderna's Cancer Vaccine Could Change America in 7 Surprising Ways

For context, a breakthrough cancer vaccine developed by Moderna and Merck is fueling hopes that the next revolution in medicine could be as transformative as the arrival of antibiotics, organ transplants or the first targeted cancer drugs.

Key points

• The technology behind Moderna's cancer vaccine grew out of years of mRNA research and received enormous attention during the COVID-19 pandemic.
• The treatment being studied, intismeran autogene, is a personalized mRNA therapy tailored to each patient's tumor and administered alongside Merck's immunotherapy Keytruda.
• The data will be presented at an upcoming international medical session, a Moderna spokesperson informed Newsweek.
• Cancer is already among the most expensive diseases to treat in the United States.
• Contact Newsweek editors on this story: Ben Kelly and Edward T.

By Anna Skinner Associate News Editor. Newsweek is a Trust Project member.

See more of our trusted coverage when you search.to see more of our trusted coverage when you search.

Moderna and Merck confirmed this week that their Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with high-risk melanoma whose tumors had been surgically removed. The treatment being studied, intismeran autogene, is a personalized mRNA therapy tailored to each patient's tumor and administered alongside Merck's immunotherapy Keytruda. The firms stated the results represent the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy.

For context, the data will be presented at an upcoming international medical session, a Moderna spokesperson informed Newsweek.

"Pending regulatory feedback, intismeran could be available as soon as next year, " the spokesperson remarked.

While the vaccine has so far demonstrated positive Phase 3 results only in melanoma, Merck and Moderna are additionally studying the personalized mRNA therapy in a number of other cancers, including non-small cell lung cancer, bladder cancer and kidney cancer. Whether the approach can deliver similar benefits in those diseases remains the subject of ongoing clinical trials.

Although the treatment is still experimental and has demonstrated a positive Phase 3 result only in melanoma so far, the findings are being viewed as a potential proof of concept for a new method of cancer treatment. Unlike traditional therapies that are the same for every patient, intismeran autogene is custom-built using the unique mutations discovered in an individual's tumor. If ongoing studies in other cancers produce similar results and regulators ultimately approve the vaccine, the technology could influence far more than cancer care itself, potentially changing how treatments are developed, manufactured and delivered throughout the U.S. Healthcare system.

Cancer Could Become More Like a Chronic Disease.

For decades, cancer treatment has largely focused on removing tumors and preventing them from returning. Personalized cancer vaccines introduce a different possibility: keeping patients cancer-free for much longer after initial treatment.

Though researchers are still studying the long-term impact on survival and disease recurrence, if future studies confirm similar benefits in other cancers, personalized cancer vaccines could support some patients remain cancer-free for longer periods after treatment.

"We need better ways to prevent recurrence for patients in remission. Recurrence of cancer is a most dreaded event, " Dr. Robert Vonderheide, director of the Abramson Cancer Center at Penn Medicine and president-elect of the American Association for Cancer Research, informed Newsweek. "A vaccine to mobilize the immune system to guard against recurrence would be a gamechanger. This news means such a vaccine is probably closer to reality than we thought."

Doctors already manage diseases such as HIV and diabetes through long-term treatment strategies, and cancer could commence moving in a similar direction for certain patients. The melanoma trial's success has intensified hopes that durable immune protection may become a central part of cancer care.

Every dose of intismeran autogene is uniquely designed for an individual patient.

Unlike traditional medicines that are manufactured identically for millions of individuals, the therapy is built from the genetic fingerprint of a patient's own tumor. Moderna notes the vaccine can encode up to 34 tumor-specific targets, effectively creating a highly customized treatment. The success of the melanoma program may accelerate a broader shift toward personalized medicine, in which therapies are increasingly generated from a person's genetic information rather than selected from a standard list of drugs.

"This vaccine is just one of many vaccines – some similar, others with different approaches – that will soon be delivering clinical results, " Vonderheide remarked. "There is every reason for excitement and hope as we enter what feels like a new stage of cancer immunotherapy." AI Could Become a Routine Part of Healthcare.

Personalized medicine could drive greater employ of artificial intelligence (AI) in cancer care. Scientists are already studying how AI can support identify tumor-specific mutations and select promising neoantigens for personalized cancer vaccines. If individualized treatments become more common, healthcare systems may increasingly rely on advanced computing tools to process the genetic information needed to develop and guide those therapies.

"The individualized nature of this mRNA vaccine is very promising, because as cancers grow, they can evolve and create new mutations that make them more aggressive, " Dr. Christina Annunziata, senior vice president of extramural discovery at the American Cancer Society, informed Newsweek. "And, not everyone will have the exact same set of mutations in their cancer. This technology takes the DNA from the patient's own tumor cells, sequences it to find mutations, and compares it to the DNA sequences from their non-cancer cells. Notably, a computer algorithm then uses this information to select up to 34 different mutated gene fragments which are then created into RNA and incorporated into the personalized vaccine."

Meanwhile, the Geography of Cancer Treatment Could Change. Personalized cancer vaccines are significantly more complex than conventional drugs.

Since the therapy is individually designed using mutations identified within a patient's tumor, it differs from traditional cancer treatments that are manufactured the same way for every patient. If approved, the approach could require new clinical and manufacturing workflows to produce personalized therapies at scale.

Personalized cancer vaccines require tumor sequencing, specialized manufacturing and sophisticated laboratory capabilities. Plenty of of the institutions pioneering these therapies are major academic medical centers and specialized cancer hospitals, where patients often gain access to cutting-edge treatments through clinical trials. According to Researchers and health-policy experts have additionally, access to advanced cancer care can vary by geography and resources, raising questions regarding how personalized therapies could be delivered broadly if they become part of routine care. The Economics of Cancer Care Could Be Turned Upside Down.

At first glance, personalized vaccines may appear costly since every treatment is individually manufactured, yet preventing recurrences could save capital over time by reducing the need for extra surgeries, chemotherapy, radiation treatments, hospitalizations and long-term monitoring.

"These vaccines could avoid costs that result from expensive treatments including surgery, chemotherapy, immunotherapy, and other targeted agents, " Cathy Bradley, dean and professor at Colorado School of Public Health, informed Newsweek." In absence of the need for these more costly treatments, cancer survivors and their families can turn their attention to work or engaging in other productive activities rather than spending time on treatment, recovery, and caregiving."

Meanwhile, it remains unclear how broadly public and private insurers would cover such therapies if they reach the market. Questions regarding reimbursement, patient eligibility and out-of-pocket costs could become major factors in determining how widely personalized cancer vaccines are employed. The COVID Vaccine Debate Could Reopen.

Meanwhile, the technology behind Moderna's cancer vaccine grew out of years of mRNA research and received enormous attention during the COVID-19 pandemic.

Meanwhile, the success of an mRNA cancer therapy creates an unusual political dynamic. Americans who were skeptical of COVID vaccines may react differently to a treatment aimed at preventing cancer recurrence in patients who have already undergone surgery. Meanwhile, the breakthrough may reignite debates over mRNA technology and its role in future medicine.

As the same platform employed during the pandemic begins producing potentially life-saving cancer treatments, the development could additionally create tensions within parts of the broader vaccine-skeptical movement. It Could Trigger a New Biotech Boom.

Wall Street's reaction suggests investors believe the implications extend far beyond melanoma.

Shares of Moderna surged after the announcement, reflecting optimism that the company's personalized vaccine platform could eventually be applied to a broad range of cancers. Analysts and researchers have pointed to ongoing studies in a number of tumor types, raising the possibility of an entirely new class of precision cancer treatments.

If those efforts succeed, the breakthrough could spark a wave of investment in biotechnology, genetic medicine, vaccine development and AI-powered drug discovery. Just as the coronavirus pandemic accelerated interest in mRNA science, the melanoma results may mark the beginning of a new era in cancer treatment, one in which therapies are increasingly built for the individual patient rather than the average one.

Contact Newsweek editors on this story: Ben Kelly and Edward T. Cummins.

For now, moderna& #039; s Cancer Vaccine Could Change America in 7 Surprising Ways remains the part of the story worth watching, and further updates are likely as more details are confirmed.